Centessa Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Revenue	15	-	6.85	-	-	-	Upgrade
Gross Profit	15	-	6.85	-	-	-	Upgrade
Selling, General & Admin	50.18	50.81	53.73	55.2	43.01	1.14	Upgrade
Research & Development	178.62	150.24	124.41	155.08	96.32	9.3	Upgrade
Operating Expenses	228.8	201.06	178.14	210.28	139.33	10.44	Upgrade
Operating Income	-213.8	-201.06	-171.28	-210.28	-139.33	-10.44	Upgrade
Interest Expense	-11.13	-10.09	-9.91	-7.28	-2.55	-0.38	Upgrade
Interest & Investment Income	20.88	14.02	10.48	0.24	-	-	Upgrade
Currency Exchange Gain (Loss)	-1.3	-1.8	0.8	-2.8	-3.6	-	Upgrade
Other Non Operating Income (Expenses)	0.14	0.11	-0.33	-0.76	-0.77	0.16	Upgrade
EBT Excluding Unusual Items	-205.21	-198.82	-170.24	-220.87	-146.25	-10.66	Upgrade
Other Unusual Items	-34.1	-34.1	-5.9	3.92	-15.08	-	Upgrade
Pretax Income	-239.31	-232.91	-176.14	-216.95	-381.79	-10.66	Upgrade
Income Tax Expense	3.39	2.84	-25.06	-0.75	0.11	-	Upgrade
Net Income	-242.7	-235.76	-151.09	-216.21	-381.9	-10.66	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	-0.83	-	Upgrade
Net Income to Common	-242.7	-235.76	-151.09	-216.21	-381.07	-10.66	Upgrade
Shares Outstanding (Basic)	133	114	96	93	75	15	Upgrade
Shares Outstanding (Diluted)	133	114	96	93	75	15	Upgrade
Shares Change (YoY)	25.82%	19.02%	2.97%	24.26%	401.11%	-	Upgrade
EPS (Basic)	-1.82	-2.06	-1.57	-2.31	-5.07	-0.71	Upgrade
EPS (Diluted)	-1.82	-2.06	-1.57	-2.31	-5.07	-0.71	Upgrade
Free Cash Flow	-181.17	-142.09	-160.51	-201.68	-136.34	-10.63	Upgrade
Free Cash Flow Per Share	-1.36	-1.24	-1.67	-2.16	-1.81	-0.71	Upgrade
Gross Margin	100.00%	-	100.00%	-	-	-	Upgrade
Operating Margin	-1425.33%	-	-2499.39%	-	-	-	Upgrade
Profit Margin	-1617.99%	-	-2204.66%	-	-	-	Upgrade
Free Cash Flow Margin	-1207.80%	-	-2342.20%	-	-	-	Upgrade
EBITDA	-213.49	-200.71	-170.97	-210.15	-139.3	-10.43	Upgrade
D&A For EBITDA	0.31	0.34	0.31	0.13	0.03	0.01	Upgrade
EBIT	-213.8	-201.06	-171.28	-210.28	-139.33	-10.44	Upgrade

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q